Last reviewed · How we verify

NCT05503823

Investigating Transcranial Alternating Current Stimulation (tACS) Preconditioning Effects on Resting and Active Motor Threshold

Terminated NA Results posted Last updated 6 October 2023
What this trial tests

NA trial testing tACS or tRNS and TMS in Understand the Effects of tACS on the Brain in 6 participants. Terminated before completion.

Timeline
16 September 2022
Primary endpoint
1 July 2023
1 July 2023

Quick facts

Lead sponsorUniversity of Manitoba
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment6
Start date16 September 2022
Primary completion1 July 2023
Estimated completion1 July 2023
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of Manitoba

Who can join

Adults 18 to 95, any sex, with Understand the Effects of tACS on the Brain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Resting Motor Threshold Primary · Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS

The peak-to-peak amplitude of the muscle signal from the resting motor threshold.

Before
GroupValue95% CI
Resting Motor Threshold With tACS76.5± 26.6
After
GroupValue95% CI
Resting Motor Threshold With tACS108.7± 43.2
30 min After
GroupValue95% CI
Resting Motor Threshold With tACS130.1± 45
1 hour After
GroupValue95% CI
Resting Motor Threshold With tACS85.8± 25.1
Active Motor Threshold Secondary · Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS

Cortical silent period measured post-MEP.

Before
GroupValue95% CI
Active Motor Threshold With tACS131.1
After
GroupValue95% CI
Active Motor Threshold With tACS123.1
30 min After
GroupValue95% CI
Active Motor Threshold With tACS81.4
1 hour After
GroupValue95% CI
Active Motor Threshold With tACS108.75

Sponsor's own description

Previous studies have looked at the potential of using transcranial direct current stimulation (tDCS) to prime the brain in order to lower the resting motor threshold. The resting motor threshold (RMT) is the intensity at which repeated transcranial magnetic stimulation (rTMS) is applied for treatments. The RMT is the lowest intensity at which the participant's muscle responds with the motor evoked potential peak-to-peak amplitude greater than 50μV for 5 of 10 trials when the hand is relaxed. The active motor threshold (AMT) is the lowest intensity that produces MEP with peak-to-peak amplitude greater than 100 μV for 5 of 10 trials while the participant maintains 10-30% of maximal voluntary contraction. The RMT and AMT is different for each person and the high intensity TMS pulses can be difficult for some of the patients in the current Alzheimer's rTMS treatment study to tolerate. Therefore, if the treatment can still be applied with lower intensities, it would be more tolerable for some people. The limited research on both tDCS and transcranial alternating current stimulation (tACS) in priming the brain for TMS are not enough to determine if they are effective in priming the brain. The studies that include tDCS have small sample size and inconclusive results. The studies with tACS are using very high frequencies of 140 Hz to 250 Hz. The objective of this research study is to determine if priming the brain with tACS at 40 Hz or tRNS for 10 minutes is able to reduce the resting and active motor threshold. Therefore, for people with higher RMT and AMT, priming with tACS or tRNS could be used to lower intensities while stimulating the brain for treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Manitoba trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05503823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing